Bioinformatics study demonstrates tumor-specific expression and diagnostic utility of non-coding RNA ENST00000453316 in solid tumors, highlighting its biomarker potential.
Key Points
To evaluate the structural features, regulatory interactions, and diagnostic biomarker capacity of the non-coding RNA transcript ENST00000453316 across solid tumors.
Conducted in silico structural, regulatory, and promoter analyses of the ENST00000453316 transcript.
Assessed transcript expression and diagnostic discrimination between tumor and adjacent normal tissues across TCGA solid cancer cohorts.
Identified binding sites for 21 RNA-binding proteins, including spliceosomal factors at splice junctions and cytoplasmic factors at the terminal exon, alongside a TATA-less, CpG-poor promoter.
Showed robust tumor vs. normal tissue discrimination in lung (ROC AUC = 0.82), bladder (ROC AUC = 0.78), and colon, breast, and stomach cancers (ROC AUC = 0.71–0.75).
Demonstrated discrimination performance close to chance in kidney, thyroid, and prostate cancer cohorts.